EKF Diagnostics Holdings PLC Notice of Interim Results & Investor Presentation (8308X)
01 9월 2022 - 3:02PM
UK Regulatory
TIDMEKF
RNS Number : 8308X
EKF Diagnostics Holdings PLC
01 September 2022
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Notice of Interim Results & Investor Presentation
Notice of Results
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global
diagnostics business , confirms that the Company will announce its
interim results for the six months ended 30 June 2022 on Tuesday 20
September 2022.
Investor Presentation
Mike Salter, Chief Executive Officer, and Marc Davies, Chief
Financial Officer, will be hosting a live online presentation
relating to the interim results via the Investor Meet Company
platform at 4.30 pm on Tuesday 20 September 2022. The presentation
is open to all existing and potential investors.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
Investors who already follow EKF on the Investor Meet Company
platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO / Marc Davies, CFO Tel: +44 (0)29 2071 0570
Singer Capital Markets (Nominated Adviser Tel: +44 (0)20 7496 3000
& Joint Broker)
Aubrey Powell / George Tzimas
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben Farrow
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44
(0)7584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers and
consumables, particularly for use in the area of Hematology
and Diabetes, for use in hospital and research laboratories,
doctor's offices, blood banks and for in-field anaemia
screening programmes. EKF has an estimated 80,000
hemoglobin, hematocrit, HbA1c, glucose and lactate
analysers in regular use across more than 100 countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated
Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private
labelling, Molecular and forensic kits
Laboratory Services In September 2021, EKF completed the acquisition of
Advanced Diagnostic Laboratory LLC ("ADL Health"),
a Texas based testing laboratory certified under the
Clinical Laboratory Improvement Amendments ("CLIA")
for high complexity testing. The laboratory provides
testing for a variety of clinical, forensic and microbiological
sample types using a range of analytical techniques.
This acquisition positions EKF as a leading 'one stop'
provider of diagnostic products and services from
sample collection to results.
EKF's growth strategy to 2024 and beyond can be summarised
as:
-- continuing innovation in products and services in Point-of-Care,
Central Laboratory and Life Sciences leveraging new and existing
routes to market and relationships;
-- investment in expanded production and kitting capabilities to offer
a suite of diagnostic Contract Manufacturing solutions to third
party businesses;
-- expansion of CLIA Laboratories Testing offering, building on the
acquired capabilities in ADL Health; and
-- concluding complementary earnings-enhancing acquisitions with key
strategic value.
EKF will also continue to generate enhanced shareholder value
through:
-- a progressive dividend policy; and
-- its agreement with Mount Sinai Innovation Partners ("MSIP"), which
allows us advanced access to innovative commercial opportunities
such as those already seen with Renalytix plc, Verici Dx plc and
Trellus Health plc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAKPFDADAEFA
(END) Dow Jones Newswires
September 01, 2022 02:02 ET (06:02 GMT)
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
